AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05503966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attentional Bias Modification
Description: The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
Study NCT05503966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: The ABM task is based on a computerized visual Dot-probe task. In the dot-probe task paired stimuli of negative (angry and fearful), positive (happy) or neutral faces are presented, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. In the ABM condition, probes are in the same locus as the more positive/less negative stimuli in 87% of the trials, as opposed to 13% with probes in the same locus as more negative/less positive stimuli. Thus, when completing the ABM, participants should learn to deploy their attention toward the relatively more positive stimuli, and in this way develop a more positive AB.
Study NCT05591573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index drink
Description: Fruit flavoured drink with low glycemic index sugar (300 ml)
Study NCT05591573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycemic index drink
Description: Fruit flavoured drink with high glycemic index sugar (300 ml)
Study NCT06325644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: The diet intervention will start after all baseline testing is complete
Study NCT06325644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ketone/Glucose Monitoring
Description: KetoMojo hand-held glucometer will be used daily to monitor dietary intervention adherence.
Study NCT06325644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CGM/CKM
Description: Continuous Ketone/Glucose Monitor will be applied at the start of Test Day 1. The sensor will be checked by the study team at each test day and will be removed and replaced by a fresh sensor at \~2- week intervals during the study. The sensor will be removed at the end of the final test day.
Study NCT06325644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood samples will be collected according to the schedule in Figure 1
Study NCT06325644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Composition
Description: DEXA Scanning will be done pre-, mid-, and post- intervention.
Study NCT06325644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in glomerular filtration rate (mg/mmol) via magnetic resonance imaging (MRI) .
Description: Changes in glomerular filtration rate will be assessed via magnetic resonance imagining conducted by trained professionals. MRI imaging analyses will determine cardiac function. Trained imaging professionals will analyze the images to determine overall change (mg/mmol).
Study NCT05876949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT03
Description: AVT03 will be given as 1 time subcutaneous injection
Study NCT05876949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Xgeva (denosumab) will be given as 1 time subcutaneous injection
Study NCT05255796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one-piece
Description: Patients underwent phacoemulsification cataract surgery with one-piece IOL implantation.
Study NCT05255796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plate-haptic
Description: Patients underwent phacoemulsification cataract surgery with plate-haptic IOL implantation.
Study NCT06016491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Depending on the preparation and compression time on each point, an average of 10 minutes was applied to each woman, and then the person were asked to apply it to themselves. After making sure that the women learned, they were asked to apply acupressure on their own. They applied a total of 12 sessions, three times a week for a total of four weeks.
Study NCT06016491 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Compression was applied on the bone region where the meridians did not pass, parallel to the KD1 and SP6 points (approximately 1-1.5 cm away). Similar to the acupressure group, the sham group was treated with symmetrical extremities and for similar durati
Study NCT05908630 — intervention group
Intervention type: OTHER
Intervention: Hypothermia
Description: Accidental hypothermia is defined as: an involuntary drop in core body temperature \<35C
Study NCT04996550 — intervention group
Intervention type: DRUG
Intervention: Carvedilol
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Study NCT04996550 — intervention group
Intervention type: DRUG
Intervention: Metoprolol Succinate
Description: To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Study NCT05176795 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Comparaison of the gut microbiota composition
Study NCT05440123 — intervention group
Intervention type: OTHER
Intervention: screening for bronchopulmonary cancer
Description: The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation
Study NCT05228535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Human milk fortifier
Description: Human milk fortifier added to human breast milk at day 1 vs day 8 of feeds
Study NCT06566170 — intervention group
Intervention type: DRUG
Intervention: Donanemab
Description: Administered IV
Study NCT05577481 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: sham iTBS combined with antidepressants
Description: Two sessions of sham prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
Study NCT05577481 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iTBS combined with antidepressants
Description: Two sessions of prolonged iTBS (1800 pulses) per day over 10 days combined with antidepressants.
Study NCT05905601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NORTH
Description: NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.
Study NCT05905601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NORTH Lite
Description: NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources.
Study NCT05445583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System (MES)
Description: MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
Study NCT05445583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Accountability (SA)
Description: Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
Study NCT05445583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (SMS)
Description: SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
Study NCT05445583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Tracking (PAT)
Description: All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
Study NCT06566170 — intervention group
Intervention type: DRUG
Intervention: Usual Care
Description: Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
Study NCT05913713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Intervention Period
Description: Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
Study NCT05913713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12-week Intervention Period
Description: Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.
Study NCT05913713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Observation Period
Description: After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
Study NCT05913713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12-week Observation Period
Description: After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
Study NCT05961111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study NCT06009991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).
Study NCT06009991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance
Study NCT05064358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study NCT06078371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid-free pain treatment
Description: Pain treatment includes any medications up to the medical team's discretion aside from opioids.
Study NCT06411327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented reality
Description: Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.
Study NCT06411327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCD Screen
Description: LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
Study NCT05927519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq video laryngoscope
Description: airtraq video laryngoscope will be used for intubations
Study NCT05927519 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: airtraq video laryngoscope
Description: airtraq video laryngoscope will be used for intubations
Study NCT05107011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-015 for Injections
Description: Initial dose - MTD ; Q2W ; intravenous infusion
Study NCT05130320 — intervention group
Intervention type: OTHER
Intervention: Not Interventional their treatments are their routine NHS care
Description: Not Interventional their treatments are their routine NHS care
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT05267470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT05222620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05222620 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Undergo single fraction SRS
Study NCT05222620 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Undergo fractionated SRS
Study NCT05222620 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06651151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + pembrolizumab
Description: LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
Study NCT04793204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: oral
Study NCT05083611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GraMI
Description: The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT
Study NCT05592145 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ViOptix
Description: ViOptix machine
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001 injection
Description: 360 mg，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 50 mg/m\^2，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m\^2，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC=5，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab injection
Description: 15 mg/kg，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab injection
Description: 15 mg/kg，Q3W，IV infusion
Study NCT05715840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SG001 placebo
Description: Q3W，IV infusion
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils
Study NCT04616313 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.
Study NCT04616313 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.
Study NCT05523024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The probiotic group will receive one capsule of the probiotic mixture (dose:1x109 colony forming units (CFU) per day in one dose (before breakfast). The PRO preparation will contain the following bacterial strains: 50% Lactococcus lactis Rosell® - 1058, 25% Lactobacillus casei Rosell® - 215, 12,5% Lactobacillus helveticus Rosell® - 52, 12,5% Bifidobacterium bifidum Rosell® - 71). Probiotics will be administered orally.
Study NCT05523024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: The berberine group will receive 1500 mg of Berberine (Berberine hydrochloride 97% extract of Berberis aristata) per day in 3 doses. Berberine will be administered orally, before breakfast, dinner, and before supper.
Study NCT05523024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a placebo. Placebo will contain only the excipients and will be administered orally for 24 weeks. Placebo in no way: color, taste, smell, form of taking, the dosage will not differ from the preparations tested. However, it will not contain probiotcs or berberine. Placebo will be orally administered three times a day: before breakfast, dinner, and supper (6.00-7.00 p.m.). To meet the GCP conditions, subjects from all groups will receive the same number of capsules (six) per day.
Study NCT05523024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotc and Berberine
Description: Probiotics and Berberine groupwill receive both: a probiotics mixture (as in PRO group: 1x109 CFU/day; in one dose) and 1500 mg/day of Berberine (Berberine hydrochloride 97% extract of Berberis aristata; in 3 doses). Probiotcs and berberine will be administered orally before breakfast, before dinner, and before supper.
Study NCT06369597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic telesurgery
Description: Telesurgery by domestic surgical robot
Study NCT05974384 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No Music
Description: No listening to music while intervention is carried out
Study NCT05974384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Listening to music while intervention is carried out